PDCD1 and neoplasm: Evidence has increasingly accumulated that anti-angiogenic therapy exerts immunomodulatory effects on the tumor microenvironment, which appears to enhance the efficacy of anti-PD-1 monoclonal antibody by normalizing abnormal tumor vessels and increasing the infiltration of immune effector cells into tumors (14, 30, 31).